**Neurological manifestations of SARS-CoV-2 infection in hospitalised children** and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health. 2021 Sep;5(9):631-641.

Background: The spectrum of neurological and psychiatric complications associated with pediatric SARS-CoV-2 infection is poorly understood. Aim of study was to analyze the range and prevalence of these complications in hospitalized children and adolescents.

Methods: Prospective national cohort study in the UK using an online network of secure rapidresponse notification portals. Paediatric neurologists notified any children and adolescents (age <18 years) admitted to hospital with neurological or psychiatric disorders. Patients were excluded if they did not have a neurological consultation or neurological investigations or both, or did not meet the definition for confirmed SARS-CoV-2 infection (a positive PCR of respiratory or spinal fluid samples, serology for anti-SARS-CoV-2 IgG, or both), or the Royal College of Paediatrics and Child Health criteria for Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 ( PIMS-TS )also known as multisystem inflammatory syndrome in children (MIS-C). Patients were classified as having either primary neurological disorder associated with COVID-19 (COVID-19 neurology group) or PIMS-TS with neurological features (PIMS-TS neurology group)

# **ACADEMIC P.E.A.R.L.S**

Pediatric Evidence And Research Learning Snippet



## **Neurological manifestations of SARS-CoV-2 infection** in hospitalized children

Results: 52 out of 1334 COVID-19 hospitalized cases (2nd Apr 2020 - Feb 1st 2021) had neurological manifestations. Estimated prevalence was 3.8 cases /100 pediatric patients.

- ·Median age was 9 years (range 1–17 years)
- ·12 (23%) patients had respiratory symptoms at admission
- ·8 (15%) patients presented with isolated neurological or psychiatric features (PCR for respiratory secretions was positive for SARS-CoV-2).
- ·Cases were classified into two groups: 27 (52%) in COVID-19 neurology group and 25 (48%) into PIMS-TS neurology group. Neurological disorders were clearly different in the two groups.
- ·Recognized neuro-immune disorders more common in COVID-19 neurology group (48% Vs < 1% in PIMS-TS neurology; p=0.0003). Common neuro-immune disorders seen were : Guillain-Barré syndrome (n=5); acute disseminated encephalomyelitis (ADEM) in 4 patients(3 had myelin oligodendrocyte glycoprotein (MOG) antibodies); other acute demyelinating syndromes (n=3) and autoimmune encephalitis(n=1). Status epilepticus, movement disorders, psychosis, isolated encephalopathy, and transient ischaemic attack were also seen.
- ·More patients in PIMS-TS neurology had encephalopathy (80% Vs 52% in COVID-19 neurology; p=0.0048), intensive care admissions (88% Vs 22% in COVID-19 neurology; p=0.0001), systemic features(100% Vs 56% in COVID-19 neurology p=0.023), abnormal neuro-imaging (74% Vs 44% in COVID-19 neurology p=0.036) and received immunomodulatory treatment (88% vs 44% in COVID-19 neurology; p=0.045).
- ·In-spite of higher intensive care need in PIMS-TS, the overall outcome was similar in both groups. (Discharged with disability; COVID-19 neurology (37% Vs 28% PIMS-TS;p=0.048)

Conclusions: Neurological manifestations are different in patients without PIMS-TS versus those with PIMS-TS.

Key-Message: Identification of clear differences between two groups could help physicians in management of patients.

#### EXPERT COMMENT



"Although uncommon yet a wide spectrum of neurological complications are being reported in children with COVID-19. Children with severe disease or multi-system inflammatory syndrome (MIS-C) are at a higher risk of developing neurological complication. Neurological illness can develop during or after recovery from COVID-19. Therefore all children presenting with acute neurological illness must be screened for COVID-19."

#### Dr Anita Sharma

MD, DM(Pediatric Neurology-AIIMS, Delhi) Professor & Incharge Child Neurology Faculty of Medicine & Health Sciences S.G.T University Gurugram

With warm regards,

## DR MANINDER S DHALIWAL

IAP NATIONAL PRESIDENT 2021

DR. PIYUSH GUPTA DR REMESH KUMAR R. IAP PRESIDENT 2022

**BASAVARAJA** 

GEN. 2021 - 22

HON. SECRETARY

DR BAKUL JAYANT DR G.V. **PAREKH** IAP PRESIDENT 2020

## Reference

Ray STJ, Abdel-Mannan O, Sa M, Fuller C, Wood GK, Pysden K, Yoong M, McCullagh H, Scott D, McMahon M, Thomas N, Taylor M, Illingworth M, McCrea N, Davies V, Whitehouse W, Zuberi S, Guthrie K, Wassmer E, Shah N, Baker MR, Tiwary S, Tan HJ, Varma U, Ram D, Avula S, Enright N, Hassell J, Ross Russell AL, Kumar R, Mulholland RE, Pett S, Galea I, Thomas RH, Lim M, Hacohen Y, Solomon T, Griffiths MJ, Michael BD, Kneen R; CoroNerve study group. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health. 2021 Sep;5(9):631-641. doi: 10.1016/S2352-4642(21)00193-0. Epub 2021 Jul 15. Erratum in: Lancet Child Adolesc Health. 2021 Jul 28